A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
|Articles|February 26, 2011
CL V2 Pediatrics - Allergy Medications
Advertisement
Fexofenadine HCl and Pseudoephedrine HCl (Allegra-D)
Diphenhydramine Hydrochloride (Benadryl Injection Solution)
Clemastine Fumarate
Mometasone Furoate (Asmanex Inhalent)
Azelastine Hydrochloride (Astelin Spray)
Desloratadine (Clarinex)
Epinephrine
Advertisement
Related to this article
FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.
Jon Matthew Farber, MD, shares his thoughts on the use of noninvasive brain stimulation for ADHD.
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
A meta-analysis of 7 real-world studies found maternal RSVpreF 78% effective against RSV LRTI hospitalization in infants up to 6 months.
In 5.2 million US infants, newborn vitamin K nonreceipt rose to 6.8% by 2025 and was tied to a 47% higher bleeding risk by 6 months.
New real-world data reveal delays and disparities in nirsevimab administration, highlighting opportunities to improve timely RSV protection for infants.
Jessica Nash, MD, IBCLC, shares strategies for assessing breastfeeding, identifying latch problems, and connecting families with lactation resources.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA investigates malignancy risk with SMA gene therapy Zolgensma
2
Maternal RSVpreF 78% effective against infant RSV hospitalization
3
Air pollution tied to higher pediatric atopic dermatitis burden
4
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
5